Business Context and Reporting Period
Propanc Biopharma, Inc. filed this Form 8-K on August 28, 2018, reporting the entry into material definitive agreements involving the issuance of convertible promissory notes. The company is incorporated in Delaware with principal executive offices in Australia.
Key Financial Metrics and Debt Obligations
The filing details two new debt instruments issued in late August 2018:
- Power Up Lending Group Ltd. Note: Principal amount of $53,000 with an 8% annual interest rate. Net proceeds of $50,000 are designated for general working capital. The note matures on August 28, 2019.
- Eagle Equities, LLC Note: Principal amount of $105,000 with an 8% annual interest rate. After a $5,000 deduction for legal expenses, net proceeds of $100,000 were received. Approximately $75,400 of these proceeds are intended to repay existing debt, with the remainder for working capital. The note matures on August 29, 2019.
The filing does not provide current revenue, profit, cash flow, or margin data, as this is a current report focused on specific financing events rather than periodic financial performance.
Material Changes and Terms
The primary material change is the incurrence of new debt obligations with aggressive conversion and prepayment terms:
- Conversion Terms: Both notes allow conversion into common stock. The Power Up Note has a floor conversion price of $0.065, subject to market price adjustments. The Eagle Equities Note converts at 60% of the lowest closing bid price (or 50% if trading is restricted).
- Prepayment Penalties: Both notes carry significant prepayment premiums if paid early. The Power Up Note premiums range from 112% to 137% of the face amount depending on the timing. The Eagle Equities Note premiums range from 130% to 150%.
- Default Provisions: Upon an event of default, interest rates increase to 22% (Power Up) and 24% (Eagle Equities). The Power Up Note requires payment of 150% of the outstanding principal plus accrued interest. The Eagle Equities Note includes specific penalties for delisting or loss of bid price, increasing the principal by 20% to 50%.
Outlook, Risks, and Contingencies
Management intends to use the proceeds to fund general working capital and reduce existing debt. Significant risks and contingencies identified in the agreements include:
- Dilution Risk: Conversion features include discounts to market price and low floor prices, which could result in significant dilution to existing shareholders.
- Liquidity and Default Risk: The high prepayment premiums and default interest rates create substantial financial pressure. Default triggers include failure to maintain share reserves, delisting, or failure to file periodic reports.
- Asset Restrictions: The Power Up Note covenants restrict the company from selling or disposing of substantially all assets without lender consent.
Investor Verification Checklist
- Verify the company's current cash position and ability to service the new debt without triggering default penalties.
- Confirm the total outstanding debt load, including the $75,400 of existing debt targeted for repayment by the Eagle Equities proceeds.
- Review the company's compliance status with SEC reporting obligations to avoid default triggers related to delinquency.
- Assess the potential dilution impact if the notes are converted at the specified discount rates.
- Check the current trading status and bid price of the common stock to evaluate the conversion price mechanics.